Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis
Open accessThe DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Endoscopic retrograde cholangiography (ERC) is a mainstay of therapy in patients with primary sclerosing cholangitis (PSC) and obstructive cholestasis. Patients with liver cirrhosis have an increased risk of surgical complications and are more susceptible to infections. Since PSC often progresses to cirrhosis, we aimed to assess whether ERC is associated with increased risk of complications in patients with PSC and cirrhosis. METHODS: Out of 383 patients with PSC, 208 patients received endoscopic treatment between 2009-2017. Seventy patients had cirrhosis when ERC was performed and 138 patients had no signs of cirrhosis. Overall, 663 ERC procedures were analysed, with 250 ERC in patients with cirrhosis and 413 ERC in patients without cirrhosis. Data were analysed retrospectively from a prospectively acquired database using repeated measures logistic regression. RESULTS: Overall, 40 procedure-related complications were documented in 663 ERC interventions (6%). The rate of complications was similar between patients with and without cirrhosis (4.4% vs. 7.0%). First-time ERC was associated with a higher risk of complications (17.5% vs. 4.9%). Biliary sphincterotomy, stent placement and female sex, but not presence of liver cirrhosis, were identified as risk factors for overall complications in multivariate analysis. Patients without cirrhosis showed a significant decline of ALP and bilirubin levels after the first two interventions. In contrast, in patients with cirrhosis, ALP and bilirubin levels did not significantly decline after ERC. CONCLUSIONS: In patients with PSC, cirrhosis was not a risk factor for post-ERC complications. Therefore, cirrhosis should not preclude endoscopic intervention in patients with clear clinical indication.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Risk does not seem to be increased in patients with cirrhosis.276”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [276]
Experimental — accuracy not yet measuredIn the citing paper
“In people with PSC and cirrhosis, stricture dilation may not lead to a lasting improvement of serum liver tests 276”
From EASL Clinical Practice Guidelines on sclerosing cholangitis (2022) · cites this paper as [276]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EASL Clinical Practice Guidelines: management of cholestatic liver diseases
European Association for the Study of the Liver (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.04.009 · Cited by 1,729
Diagnosis and Management of Primary Sclerosing Cholangitis
Chapman, R., Fevery, J., Kalloo, A., Nagorney, D. M., Boberg, K. M., Shneider, B., & Gores, G. J. (2010) · Hepatology · doi:10.1002/hep.23294 · Cited by 1,224
Incidence Rates of Post-ERCP Complications: A Systematic Survey of Prospective Studies
Andriulli, A., Loperfido, S., Napolitano, G., Niro, G., Valvano, M. R., Spirito, F., Pilotto, A., & Forlano, R. (2007) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2007.01279.x · Cited by 1,199
Bacterial infections in cirrhosis: A position statement based on the EASL Special Conference 2013
Jalan, R., Fernandez, J., Wiest, R., Schnabl, B., Moreau, R., Angeli, P., Stadlbauer, V., Gustot, T., Bernardi, M., Canton, R., et al. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.01.024 · Cited by 906
Adverse events associated with ERCP
Chandrasekhara, V., Khashab, M. A., Muthusamy, V. R., Acosta, R. D., Agrawal, D., Bruining, D. H., Eloubeidi, M. A., Fanelli, R. D., Faulx, A. L., Gurudu, S. R., et al. (2017) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2016.06.051 · Cited by 864
Primary sclerosing cholangitis
Hirschfield, G. M., Karlsen, T. H., Lindor, K. D., & Adams, D. H. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60096-3 · Cited by 592
ACG clinical guideline: primary sclerosing cholangitis
Lindor, K. D., Kowdley, K. V., & Harrison, E. M. (2015) · American Journal of Gastroenterology · doi:10.1038/ajg.2015.112 · Cited by 524
Primary Sclerosing Cholangitis
Lazaridis, K. N., & LaRusso, N. F. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1506330 · Cited by 505
Primary sclerosing cholangitis
Dyson, J. K., Beuers, U., Jones, D. E. J., Lohse, A. W., & Hudson, M. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30300-3 · Cited by 462
Self-citation[Primary sclerosing cholangitis].
Molina Jurado, M., Ferrer, J., & Gómez, N. (1984) · PubMed · Cited by 335
Cited by
EASL Clinical Practice Guidelines on sclerosing cholangitis
Chazouilleres, O., Beuers, U., Bergquist, A., Karlsen, T. H., Levy, C., Samyn, M., Schramm, C., & Trauner, M. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.011 · Cited by 419
Self-citationPrimary sclerosing cholangitis
Manns, M. P., Bergquist, A. M., Karlsen, T. H., Levy, C., Muir, A. J., Ponsioen, C. Y., Trauner, M., Wong, G. L., & Younossi, Z. M. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00600-x · Cited by 80
“Patients with cirrhosis may be more susceptible to bacterial cholangitis because of a compromised immune status, although comparable adverse event rates after ERC in patients with versus without cirrhosis have been observed 190 .”
Tarar, Z. I., Farooq, U., Gandhi, M. H., Saleem, S., & Daglilar, E. S. (2023) · Clinical Endoscopy · doi:10.5946/ce.2023.027 · Cited by 20
Primary sclerosing cholangitis
von Seth, E., Karlsen, T. H., Tanaka, A., Ponsioen, C. Y., & Bergquist, A. M. (2026) · The Lancet · doi:10.1016/s0140-6736(25)02582-6 · Cited by 17
ERCP-Related Adverse Events in Primary Sclerosing Cholangitis: A Systematic Review and Meta-Analysis
Natt, N., Michael, F., Michael, H., Dubois, S. J., & Al‐Mazroui, A. (2022) · Canadian Journal of Gastroenterology and Hepatology · doi:10.1155/2022/2372257 · Cited by 18
“)ree retrospective cohorts [25, 28, 31], one retrospective case-control [27], and one RCT [32] contributed to this meta-analysis.”
BackgroundMethodResultInfluential
Metadata
- Authors
- Peiseler, M., Reiners, D., Pinnschmidt, H. O., Sebode, M., Jung, F., Hartl, J., Zenouzi, R., Ehlken, H., Groth, S., Schachschal, G., Rösch, T., Weiler-Normann, C., Lohse, A. W., & Schramm, C.
- Affiliations
- University Medical Center Hamburg-Eppendorf (DE)
- Corresponding author
- Peiseler, Moritz
- Schramm, Christoph
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2018-08-20
- Volume
- 13
- Issue
- 8
- Pages
- e0202686
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC6101401
- OpenAlex
- W2888098873
- Cited by
- 17
- References
- 36
- Citations by year
- 2026: 3 · 2025: 2 · 2024: 2 · 2023: 3 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 1
- FWCI
- 0.63
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Deutsche Forschungsgemeinschaft (SFB 841, KFO306, SFB841, KFO306, SE 2665/1-1)
- Helmut and Hannelore Greve Foundation
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Gastroenterology › Gallbladder and Bile Duct Disorders
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- primary sclerosing cholangitis, liver cirrhosis, endoscopic retrograde cholangiography, biliary interventions, procedural complications, risk factors, endoscopic sphincterotomy, biliary stenting, obstructive cholestasis
- MeSH terms
- Sphincterotomy, Adult, Aged, Alkaline Phosphatase, Bilirubin, Cholangiopancreatography, Endoscopic Retrograde, Cholestasis, Female, Humans, Liver Cirrhosis, Male, Middle Aged, Postoperative Complications, Retrospective Studies, Risk Factors, Severity of Illness Index, Sex Factors, Cholangitis, Sclerosing, Stents, Logistic Models
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis. https://app.cochat.ai/papers/10.1371/journal.pone.0202686
- The paper
- Peiseler, M., Reiners, D., Pinnschmidt, H. O., Sebode, M., Jung, F., Hartl, J., Zenouzi, R., Ehlken, H., Groth, S., Schachschal, G., Rösch, T., Weiler-Normann, C., Lohse, A. W., & Schramm, C. (2018). Risk of endoscopic biliary interventions in primary sclerosing cholangitis is similar between patients with and without cirrhosis. PLOS ONE. https://doi.org/10.1371/journal.pone.0202686
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.